Pub. Date : 2021 Dec
PMID : 34663950
1 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
1 | CONCLUSION: We provide clinical evidence supporting the role of SLFN11 as a DDA therapy selection biomarker in SCLC and highlight the need for further clinical investigation into SLFN11 as a PARP inhibitor predictive biomarker. | dda | schlafen family member 11 | Homo sapiens |